home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

New Diagnostic: A Unique Molecular Profile for Lung Cancer

 
  March, 21 2006 18:30
your information resource in human molecular genetics
 
     
A team of researchers has found that the expression pattern of certain microRNAs, or miRNAs, may predict tumor aggressiveness in some patients with lung cancer. These findings indicate that miRNAs may represent a new class of diagnostic and prognostic tools for lung cancer. The study is a collaboration among researchers at
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; the Jikei University School of Medicine, Tokyo, Japan; National Cancer Center Research Institute, Tokyo, Japan; and the Center for Cancer Research at the National Cancer Institute (NCI), which is part of the National Institutes of Health. The study results appear in the March 13, 2006, issue of Cancer Cell.

miRNAs are small segments of genetic material called ribonucleic acid, or RNA, and are thought to control gene expression. Their actions could change the expression of cancer-related genes within a cell and lead to malignancies.

The researchers identified two miRNAs — has-mir-155 and has-let-7a-2 — that could be used as prognostic indicators in patients with adenocarcinoma, a malignancy of the mucous glands in the lungs. High levels of has-mir-155 or low levels of has-let-7a-2 were associated with poor prognosis. Specifically, overexpression of has-mir-155, or the signalling of the miRNA to change the amount of a protein produced, was the most significant indicator of this prognosis, independent of tumor stage. Although these miRNAs have been identified in other cancers, this is the first evidence linking has-mir-155 to lung cancer.

A tumor with an overexpression of has-mir-155 or reduced expression of has-let-7a-2 would indicate the need for aggressive chemotherapy or radiation treatments. Other tumors that do not show high has-mir-155 or low has-let-7a-2 levels are less aggressive, and those patients might not require more therapy.

“This study is significant because it provides another tool for studying prognosis that is independent of tumor stage,” said Curtis Harris, M.D., chief of the Laboratory of Human Carcinogenesis at NCI and co-leader of this study. “Following surgery, 50 to 60 percent of patients with stage I lung cancer will develop metastatic disease within five years. This may indicate that there are micrometastases that have not been detected by imaging, scanning or pathology.” Harris noted that “in the future, we can use miRNAs and other biological predictors to select patients who may need more aggressive treatment versus those who may not. Additional studies confirming these results are the next step before incorporating miRNA analysis into routine clinical practice.”

Lung cancer is the leading cause of death due to cancer and is primarily caused by exposure to tobacco smoke. Scientists seek to better understand the mechanisms underlying this disease, and miRNAs may provide a way to examine the regulation of cancer-related genes.

CONTACT:
NCI Media Relations Branch
301-496-6641


Message posted by: Rashmi Nemade

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.